Palisade Bio (NASDAQ:PALI – Get Free Report) and Vaxart (OTCMKTS:VXRT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
Palisade Bio has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Palisade Bio and Vaxart, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 1 | 0 | 7 | 2 | 3.00 |
| Vaxart | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares Palisade Bio and Vaxart’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -33.47% | -31.79% |
| Vaxart | 15.88% | 53.04% | 20.85% |
Valuation and Earnings
This table compares Palisade Bio and Vaxart”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $500,000.00 | 554.18 | -$16.78 million | ($0.48) | -3.31 |
| Vaxart | $47.40 million | 2.50 | $16.33 million | $0.16 | 3.04 |
Vaxart has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Vaxart beats Palisade Bio on 9 of the 15 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
